Antiepileptic Drug-Induced Cognitive Adverse Effects Potential Mechanisms and Contributing Factors

被引:122
作者
Mula, Marco [1 ]
Trimble, Michael R. [2 ]
机构
[1] Univ Piemonte Orientale, Dept Neurol, Dept Clin & Expt Med, I-28100 Novara, Italy
[2] UCL, Inst Neurol, London, England
关键词
QUALITY-OF-LIFE; NEWLY-DIAGNOSED EPILEPSY; PATIENT-BASED SCALE; ADD-ON THERAPY; FOLLOW-UP; ANTICONVULSANT DRUGS; SODIUM VALPROATE; NEUROPSYCHOLOGICAL ASSESSMENT; ASSESSING NEUROTOXICITY; REFRACTORY EPILEPSY;
D O I
10.2165/00023210-200923020-00003
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Cognitive dysfunction is frequently observed in patients with epilepsy and represents an important challenge in the management of patients with this disorder. In this respect, the relative contribution of antiepileptic drugs (AEDs) is of relevance. The fact that a considerable number of patients require AED therapy for many years, or perhaps even a lifetime, emphasizes the need to focus on the long-term adverse effects of these drugs on cognition. The most prevalent of the CNS adverse effects observed during AED therapy are sedation, somnolence, distractibility, insomnia and dizziness. Sedation, in particular, is associated with most of the commonly used AED therapies. Nevertheless, cognitive function in individuals with epilepsy may also be influenced by several factors, of which AEDs constitute only one of many putative causes. In general terms, most studies agree that some differences exist among the older AEDs with regard to the effects on cognition, and some newer generation molecules may have a better cognitive profile than older AEDs. The mechanisms of action are an obvious determinant; however, there is still a lack of evidence for differentiation between available drugs with regard to cognitive effects. Some authors have suggested that there may be different cognitive effects associated with individual drugs; however, the question as to whether there are more specific deficits related to the action of individual drugs remains unsolved. There seems to be agreement that polytherapy and high-dose treatment can produce cognitive adverse effects and when high dosages or adjunctive polytherapy is needed, the balance between benefits and disadvantages may be negatively biased against drug treatment. Thus, drug treatment requires careful balancing in the attempt to reach maximal seizure control while avoiding neurotoxic adverse effects. Finally, the mood status of the patient and clinical relevance of the information obtained by neuropsychological testing represent important variables that need to be taken into account when discussing cognitive adverse effects of AEDs.
引用
收藏
页码:121 / 137
页数:17
相关论文
共 107 条
  • [1] COGNITIVE EFFECTS OF OXCARBAZEPINE AND PHENYTOIN MONOTHERAPY IN NEWLY DIAGNOSED EPILEPSY - ONE YEAR FOLLOW-UP
    AIKIA, M
    KALVIAINEN, R
    SIVENIUS, J
    HALONEN, T
    RIEKKINEN, PJ
    [J]. EPILEPSY RESEARCH, 1992, 11 (03) : 199 - 203
  • [2] Aldenkamp A.P., 2002, The neuropsychiatry of epilepsy, P256
  • [3] Pharmacokinetics and cognitive effects of carbamazepine formulations with different dissolution rates
    Aldenkamp, AP
    Rentmeester, T
    Hulsman, J
    Majoie, M
    Doelman, J
    Diepman, L
    Schellekens, A
    Franken, M
    Olling, M
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1998, 54 (02) : 185 - 192
  • [4] The Neurotoxicity Scale .2. Results of a patient-based scale assessing neurotoxicity in patients with epilepsy
    Aldenkamp, AP
    Baker, GA
    [J]. EPILEPSY RESEARCH, 1997, 27 (03) : 165 - 173
  • [5] THE NEUROTOXICITY SCALE - THE VALIDITY OF A PATIENT-BASED SCALE, ASSESSING NEUROTOXICITY
    ALDENKAMP, AP
    BAKER, G
    PIETERS, MSM
    SCHOEMAKER, HC
    COHEN, AF
    SCHWABE, S
    [J]. EPILEPSY RESEARCH, 1995, 20 (03) : 229 - 239
  • [6] A multicenter, randomized clinical study to evaluate the effect on cognitive function of topiramate compared with valproate as add-on therapy to carbamazepine in patients with partial-onset seizures
    Aldenkamp, AP
    Baker, G
    Mulder, OG
    Chadwick, D
    Cooper, P
    Doelman, J
    Duncan, R
    Gassmann-Mayer, C
    de Haan, GJ
    Hughson, C
    Hulsman, J
    Overweg, J
    Pledger, G
    Rentmeester, TW
    Riaz, H
    Wroe, S
    [J]. EPILEPSIA, 2000, 41 (09) : 1167 - 1178
  • [7] Effects of antiepileptic drugs on cognition
    Aldenkamp, AP
    [J]. EPILEPSIA, 2001, 42 : 46 - 49
  • [8] CONTROLLED RELEASE CARBAMAZEPINE - COGNITIVE SIDE-EFFECTS IN PATIENTS WITH EPILEPSY
    ALDENKAMP, AP
    ALPHERTS, WCJ
    MOERLAND, MC
    OTTEVANGER, N
    VANPARYS, JAP
    [J]. EPILEPSIA, 1987, 28 (05) : 507 - 514
  • [9] ALDENKAMP AP, 1995, EPILEPSY CHILDREN AD
  • [10] Behaviour, cognition and epilepsy
    Aldenkamp, AR
    Bodde, N
    [J]. ACTA NEUROLOGICA SCANDINAVICA, 2005, 112 : 19 - 25